早期肺癌的最新进展
Recent advances in early stage lung cancer.
作者信息
Luna Javier, Sotoca Amalia, Fernández Pablo, Miralles Celia, Rodríguez Aurora
机构信息
Department of Radiation Oncology, Fundación Jiménez Díaz, Madrid, Spain.
Department of Radiation Oncology, Ruber International, Madrid, Spain.
出版信息
J Clin Transl Res. 2021 Apr 6;7(2):163-174. eCollection 2021 Apr 22.
Abstract
UNLABELLED
Treatment of early-stage non-small cell lung cancer has undergone considerable change in recent years. Areas of great interest to researchers include less invasive surgical methods with lower associated morbidity, indications for adjuvant chemotherapy and radiotherapy, the emergence of stereotactic body radiotherapy (SBRT) for peripheral and central or ultracentral tumors, and the probable role of adjuvant immunotherapy following surgery and SBRT, all of which may influence the management of these patients.
RELEVANCE FOR PATIENTS
At present, the treatment of early stage non-small cell lung cancer is undergoing changes associated with the evolution of existing treatments and the advent of new treatments.
摘要
未标注
近年来，早期非小细胞肺癌的治疗发生了相当大的变化。研究人员非常感兴趣的领域包括具有较低相关发病率的侵入性较小的手术方法、辅助化疗和放疗的适应症、立体定向体部放疗（SBRT）对外周、中央或超中央肿瘤的应用以及手术和SBRT后辅助免疫治疗的可能作用，所有这些都可能影响这些患者的治疗管理。
对患者的相关性
目前，早期非小细胞肺癌的治疗正在经历与现有治疗方法的演变和新治疗方法的出现相关的变化。
相似文献
1
Recent advances in early stage lung cancer.
J Clin Transl Res. 2021 Apr 6;7(2):163-174. eCollection 2021 Apr 22.
2
Stereotactic body radiotherapy (SBRT) for central and ultracentral node-negative lung tumors.
J Thorac Dis. 2020 Nov;12(11):7024-7031. doi: 10.21037/jtd-2019-cptn-01.
3
Treatment of stage I and II non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines.
Chest. 2013 May;143(5 Suppl):e278S-e313S. doi: 10.1378/chest.12-2359.
4
Stereotactic body radiation therapy in the treatment of early-stage non-small cell lung cancer.
Klin Onkol. 2023 Fall;36(4):370-377. doi: 10.48095/ccko2023370.
5
The safety and effectiveness of stereotactic body radiotherapy for central versus ultracentral lung tumors.
Radiother Oncol. 2018 Nov;129(2):277-283. doi: 10.1016/j.radonc.2018.07.001. Epub 2018 Jul 23.
6
Accelerated Hypofractionated Radiotherapy Versus Stereotactic Body Radiotherapy for the Treatment of Stage I Nonsmall Cell Lung Cancer-A Single Institution Experience With Long-Term Follow-Up.
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818806318. doi: 10.1177/1533033818806318.
7
Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
Lung Cancer. 2019 Apr;130:162-168. doi: 10.1016/j.lungcan.2019.02.023. Epub 2019 Feb 21.
8
Survival Outcome after Stereotactic Body Radiation Therapy and Surgery for Early Stage Non-Small Cell Lung Cancer: A Meta-Analysis.
J Invest Surg. 2017 Aug 22;31(5):440-447. doi: 10.1080/08941939.2017.1341573.
9
Tumor Control and Toxicity after SBRT for Ultracentral, Central, and Paramediastinal Lung Tumors.
Pract Radiat Oncol. 2019 Mar;9(2):e196-e202. doi: 10.1016/j.prro.2018.11.005. Epub 2018 Nov 26.
10
Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.
Radiother Oncol. 2019 Mar;132:188-196. doi: 10.1016/j.radonc.2018.10.017. Epub 2018 Oct 31.
引用本文的文献
1
Mutational differences between primary cancer tissue and circulating tumor cells in early-stage non-small cell lung cancer.
Transl Lung Cancer Res. 2024 Nov 30;13(11):3026-3038. doi: 10.21037/tlcr-24-709. Epub 2024 Nov 12.
2
The dynamic duo: A narrative review on the synergy between stereotactic body radiotherapy and immunotherapy in lung cancer treatment (Review).
Oncol Rep. 2024 Jul;52(1). doi: 10.3892/or.2024.8755. Epub 2024 Jun 14.
3
Ampelopsin targets in cellular processes of cancer: Recent trends and advances.
Toxicol Rep. 2022 Jul 27;9:1614-1623. doi: 10.1016/j.toxrep.2022.07.013. eCollection 2022.
4
Licorice ( L.)-Derived Phytochemicals Target Multiple Signaling Pathways to Confer Oncopreventive and Oncotherapeutic Effects.
Onco Targets Ther. 2022 Nov 30;15:1419-1448. doi: 10.2147/OTT.S366630. eCollection 2022.
5
Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.
Naunyn Schmiedebergs Arch Pharmacol. 2023 Feb;396(2):191-212. doi: 10.1007/s00210-022-02298-0. Epub 2022 Oct 10.
6
STAT signaling as a target for intervention: from cancer inflammation and angiogenesis to non-coding RNAs modulation.
Mol Biol Rep. 2022 Sep;49(9):8987-8999. doi: 10.1007/s11033-022-07399-w. Epub 2022 Apr 26.
本文引用的文献
1
A Randomized, Phase III Study of Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) in High-Risk Patients with Stage I Non-Small Cell Lung Cancer (NSCLC).
Ann Surg Oncol. 2022 Aug;29(8):4686-4687. doi: 10.1245/s10434-022-11584-3. Epub 2022 May 6.
2
Bronchoscopic treatments for early-stage peripheral lung cancer: Are we ready for prime time?
Respirology. 2020 Sep;25(9):944-952. doi: 10.1111/resp.13903. Epub 2020 Jul 8.
3
Long-term survival outcome after lobectomy in patients with clinical T1 N0 lung cancer.
J Thorac Cardiovasc Surg. 2020 Jan 11. doi: 10.1016/j.jtcvs.2019.12.072.
4
Long-Term Oncologic Outcomes After Robotic Lobectomy for Early-stage Non-Small-cell Lung Cancer Versus Video-assisted Thoracoscopic and Open Thoracotomy Approach.
Clin Lung Cancer. 2020 May;21(3):214-224.e2. doi: 10.1016/j.cllc.2019.10.004. Epub 2019 Oct 13.
5
Nonintubated thoracoscopic surgery for early-stage non-small cell lung cancer.
Gen Thorac Cardiovasc Surg. 2020 Jul;68(7):733-739. doi: 10.1007/s11748-019-01220-5. Epub 2019 Oct 11.
6
Stereotactic Radiation for Ultra-Central Lung Tumors: Good Idea, or Ultra-Risky?
Int J Radiat Oncol Biol Phys. 2019 Mar 15;103(4):788-791. doi: 10.1016/j.ijrobp.2018.10.008. Epub 2019 Feb 20.
7
Adjuvant chemotherapy following stereotactic body radiotherapy for early stage non-small-cell lung cancer is associated with lower overall: A National Cancer Database Analysis.
Lung Cancer. 2019 Apr;130:162-168. doi: 10.1016/j.lungcan.2019.02.023. Epub 2019 Feb 21.
8
Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial.
Lancet Oncol. 2019 Apr;20(4):494-503. doi: 10.1016/S1470-2045(18)30896-9. Epub 2019 Feb 12.
9
Is stereotactic body radiotherapy for ultra-central lung tumor a feasible option? A systemic review and meta-analysis.
Int J Radiat Biol. 2019 Mar;95(3):329-337. doi: 10.1080/09553002.2019.1552375. Epub 2019 Feb 11.
10
Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503).
Lancet Respir Med. 2018 Dec;6(12):915-924. doi: 10.1016/S2213-2600(18)30411-9. Epub 2018 Nov 12.
Zotero 插件